Yang Xinhai, Solomon Sandra, Fraser Lauren R, Trombino Anthony F, Liu Donghui, Sonenshein Gail E, Hestermann Eli V, Sherr David H
Department of Environmental Health, Boston University School of Public Health, Boston, Massachusetts 02118, USA.
J Cell Biochem. 2008 May 15;104(2):402-17. doi: 10.1002/jcb.21630.
The aryl hydrocarbon receptor (AhR) is a receptor/transcription factor which regulates cytochrome P450 (CYP) gene transcription and which is activated by environmental carcinogens, some of which are associated with increased breast cancer risk. Here, we show that the AhR is over-expressed and constitutively active in human and rodent mammary tumors, suggesting its ongoing contribution to tumorigenesis regardless of tumor etiology. AhR regulation of CYP1A1 and CYP1B1 was studied to determine if constitutively active AhR effects the same transcriptional outcomes as environmental chemical-activated AhR. Elevated AhR and CYP1B1 but not CYP1A1 before tumor formation in a rat model of mammary tumorigenesis suggested differential CYP1B1 regulation by a constitutively active AhR. This hypothesis was tested with human mammary gland cell lines which hyper-express AhR and CYP1B1 but which express little or no CYP1A1. CYP1B1 expression was diminished by repression of AhR activity or by AhR knockdown, demonstrating AhR control of basal CYP1B1 levels. ChIP assays demonstrated constitutive AhR binding to both CYP1A1 and CYP1B1 promoters, demonstrating that differential CYP1A1 and CYP1B1 regulation by constitutively active AhR does not result from different amounts of promoter-bound AhR. While increasing AhR binding to both CYP1A1 and CYP1B1, 2,3,7,8-tetrachlorodibenzo-p-dioxin induced CYP1A1 mRNA in both a malignant and non-malignant line but increased only CYP1B1 mRNA in the malignant line, again demonstrating that the level of promoter binding does not necessarily correlate with gene mRNA levels. These studies suggest that constitutively active AhR mediates different molecular outcomes than environmental chemical-activated AhR, and further implicate the AhR in mammary tumorigenesis.
芳基烃受体(AhR)是一种受体/转录因子,可调节细胞色素P450(CYP)基因转录,并被环境致癌物激活,其中一些致癌物与乳腺癌风险增加有关。在此,我们表明AhR在人类和啮齿动物乳腺肿瘤中过度表达且持续激活,这表明无论肿瘤病因如何,它都在肿瘤发生过程中持续发挥作用。研究了AhR对CYP1A1和CYP1B1的调节作用,以确定持续激活的AhR是否会产生与环境化学物质激活的AhR相同的转录结果。在大鼠乳腺肿瘤发生模型中,肿瘤形成前AhR和CYP1B1升高,但CYP1A1未升高,这表明持续激活的AhR对CYP1B1的调节存在差异。用高表达AhR和CYP1B1但很少或不表达CYP1A1的人乳腺细胞系验证了这一假设。通过抑制AhR活性或敲低AhR可使CYP1B1表达减少,这表明AhR可控制基础CYP1B1水平。染色质免疫沉淀(ChIP)分析表明,持续激活的AhR与CYP1A1和CYP1B1启动子均有结合,这表明持续激活的AhR对CYP1A1和CYP1B1的不同调节并非源于启动子结合的AhR数量不同。虽然增加AhR与CYP1A1和CYP1B1的结合,但2,3,7,8 - 四氯二苯并 - 对 -二恶英在恶性和非恶性细胞系中均诱导CYP1A1 mRNA表达,但仅在恶性细胞系中增加CYP1B1 mRNA表达,这再次表明启动子结合水平不一定与基因mRNA水平相关。这些研究表明,持续激活的AhR介导的分子结果与环境化学物质激活的AhR不同,并进一步表明AhR与乳腺肿瘤发生有关。